UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 82

Sortiert nach

Calibration of the IQVIA Core Diabetes Model to the stroke outcomes from the SUSTAIN 6 cardiovascular outcomes trial of once-weekly semaglutide

Journal of medical economics, 2023, Vol.26 (1), p.1019-1031

2023

Link zum Volltext

Verfügbarkeit prüfen

Healthcare resource utilization and direct medical costs associated with index and recurrent Clostridioides difficile infection: a real-world data analysis

Journal of medical economics, 2020-06, Vol.23 (6), p.603-609

2020

Link zum Volltext

Verfügbarkeit prüfen

Evaluating the burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the UK

Journal of medical economics, 2020-01, Vol.23 (1), p.98-105

2020

Link zum Volltext

Verfügbarkeit prüfen

Short-term costs in patients with chronic kidney disease treated with dapagliflozin: a retrospective cohort study

Expert review of pharmacoeconomics & outcomes research, 2023-10, Vol.23 (9), p.1057-1066

2023

Link zum Volltext

Verfügbarkeit prüfen

Improved medication adherence in COPD patients using tiotropium or tiotropium olodaterol with the HealthPrize digital behavior change program

Expert review of pharmacoeconomics & outcomes research, 2023-12, p.1-15

2023

Link zum Volltext

Verfügbarkeit prüfen

Economic burden of comorbidities among COPD Patients hospitalized for acute exacerbations: an analysis of a commercially insured population

Expert review of pharmacoeconomics & outcomes research, 2022-06, Vol.22 (4), p.683-690

2022

Link zum Volltext

Verfügbarkeit prüfen

Impact of Pseudomonas aeruginosa on resource utilization and costs in patients with exacerbated non-cystic fibrosis bronchiectasis

Journal of medical economics, 2024-01, Vol.27 (1), p.671-677

2024

Link zum Volltext

Verfügbarkeit prüfen

Real world treatment patterns, healthcare resource use and costs in patients with advanced or metastatic non-small cell lung cancer by EGFR mutation type

Journal of medical economics, 2024, Vol.27 (1), p.219-37

2024

Link zum Volltext

Verfügbarkeit prüfen

Estimating the impact of biosimilar entry on prices and expenditures in rheumatoid arthritis: a case study of targeted immune modulators

Journal of medical economics, 2022-12, Vol.25 (1), p.1118-1126

2022

Link zum Volltext

Verfügbarkeit prüfen

Impact of choice of inhalers for asthma care on global carbon footprint and societal costs: a long-term economic evaluation

Journal of medical economics, 2022-12, Vol.25 (1), p.940-953

2022

Link zum Volltext

Verfügbarkeit prüfen

Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin

Journal of medical economics, 2020-02, Vol.23 (2), p.193-203

2020

Link zum Volltext

Verfügbarkeit prüfen

Cost-effectiveness of a novel hybrid closed-loop system compared with continuous subcutaneous insulin infusion in people with type 1 diabetes in the UK

Journal of medical economics, 2021-01, Vol.24 (1), p.883-890

2021

Link zum Volltext

Verfügbarkeit prüfen

Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective

Journal of medical economics, 2020-11, Vol.23 (11), p.1311-1320

2020

Link zum Volltext

Verfügbarkeit prüfen

Cost of patients with hemophilia A treated with standard half-life or extended half-life FVIII in Spain

Expert review of pharmacoeconomics & outcomes research, 2021-03, Vol.21 (2), p.315-320

2021

Link zum Volltext

Verfügbarkeit prüfen

Continuing trends in U.S. brand-name and generic drug competition

Journal of medical economics, 2021-01, Vol.24 (1), p.908-917

2021

Link zum Volltext

Verfügbarkeit prüfen

Economic burden and risk factors of migraine disease progression in the US: a retrospective analysis of a commercial payer database

Journal of medical economics, 2020-11, Vol.23 (11), p.1356-1364

2020

Link zum Volltext

Verfügbarkeit prüfen

Healthcare resource utilization and costs of rivaroxaban versus warfarin among non-valvular atrial fibrillation (NVAF) patients with obesity in a US population

Journal of medical economics, 2021-01, Vol.24 (1), p.550-562

2021

Link zum Volltext

Verfügbarkeit prüfen

The impact of copay assistance on patient out-of-pocket costs and treatment rates with ALK inhibitors

Journal of medical economics, 2019-05, Vol.22 (5), p.414-420

2019

Link zum Volltext

Verfügbarkeit prüfen

The association between the severity of chronic kidney disease and medical costs among patients with type 2 diabetes

Journal of medical economics, 2019-05, Vol.22 (5), p.447-454

2019

Link zum Volltext

Verfügbarkeit prüfen

Federal government-interest patent disclosures for recent top-selling drugs

Journal of medical economics, 2019-12, Vol.22 (12), p.1-1267

Long, Genia

2019

Link zum Volltext

Verfügbarkeit prüfen

Healthcare resource utilization and costs among psoriasis patients treated with biologics, overall and by disease severity

Journal of medical economics, 2018-08, Vol.21 (8), p.745-754

2018

Link zum Volltext

Verfügbarkeit prüfen

Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US

Journal of medical economics, 2018-11, Vol.21 (11), p.1110-1118

2018

Link zum Volltext

Verfügbarkeit prüfen

Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder

Journal of medical economics, 2018-09, Vol.21 (9), p.888-901

2018

Link zum Volltext

Verfügbarkeit prüfen

The cost-effectiveness of dulaglutide versus insulin glargine for the treatment of type 2 diabetes mellitus in Japan

Journal of medical economics, 2018-05, Vol.21 (5), p.1-496

2018

Link zum Volltext

Verfügbarkeit prüfen

Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications

Expert review of pharmacoeconomics & outcomes research, 2021-07, Vol.21 (4), p.527-540

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 82

Suche als RSS-Feed

Aktive Filter

ThemaHealth Care Sciences & Services

KollektionTaylor & Francis Online

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(82)
Mit Volltextzugriff
(57)

Publikationsform

Artikel
(82)

Sprache

Englisch
(82)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

1 weiteren anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Calibration of the IQVIA Core Diabetes Model to the stroke outcomes from the SUSTAIN 6 cardiovascular outcomes trial of once-weekly semaglutide

Healthcare resource utilization and direct medical costs associated with index and recurrent Clostridioides difficile infection: a real-world data analysis

Evaluating the burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the UK

Short-term costs in patients with chronic kidney disease treated with dapagliflozin: a retrospective cohort study

Improved medication adherence in COPD patients using tiotropium or tiotropium olodaterol with the HealthPrize digital behavior change program

Economic burden of comorbidities among COPD Patients hospitalized for acute exacerbations: an analysis of a commercially insured population

Impact of Pseudomonas aeruginosa on resource utilization and costs in patients with exacerbated non-cystic fibrosis bronchiectasis

Real world treatment patterns, healthcare resource use and costs in patients with advanced or metastatic non-small cell lung cancer by EGFR mutation type

Estimating the impact of biosimilar entry on prices and expenditures in rheumatoid arthritis: a case study of targeted immune modulators

Impact of choice of inhalers for asthma care on global carbon footprint and societal costs: a long-term economic evaluation

Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin

Cost-effectiveness of a novel hybrid closed-loop system compared with continuous subcutaneous insulin infusion in people with type 1 diabetes in the UK

Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective

Cost of patients with hemophilia A treated with standard half-life or extended half-life FVIII in Spain

Continuing trends in U.S. brand-name and generic drug competition

Economic burden and risk factors of migraine disease progression in the US: a retrospective analysis of a commercial payer database

Healthcare resource utilization and costs of rivaroxaban versus warfarin among non-valvular atrial fibrillation (NVAF) patients with obesity in a US population

The impact of copay assistance on patient out-of-pocket costs and treatment rates with ALK inhibitors

The association between the severity of chronic kidney disease and medical costs among patients with type 2 diabetes

Federal government-interest patent disclosures for recent top-selling drugs

Healthcare resource utilization and costs among psoriasis patients treated with biologics, overall and by disease severity

Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US

Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder

The cost-effectiveness of dulaglutide versus insulin glargine for the treatment of type 2 diabetes mellitus in Japan

Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications

Aktive Filter

Suchergebnisse filtern